Description

The global wound biologics market is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 11.5% during the forecast period, according to data and analytics company StrategyHelix. Rise in adoption of evidence-based treatments for chronic wounds, rapid increase in geriatric population, rise in disposable income in developing economies, rise in awareness toward advanced wound care treatment & management are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for wound biologics. The global wound biologics market is segmented on the basis of product, wound type, end user, and region. By product, it is categorized into skin substitutes (CTPs), and others. The skin substitutes (CTPs) segment held the largest market share in 2020. By wound type, the wound biologics market is divided into acute wounds, and chronic wounds. Based on end user, the wound biologics market is divided into hospitals, and clinics.

The report has profiled some of the key players of the market such as Allergan plc (AbbVie Inc.), Amniox Medical Inc., Cook Biotech Inc., Integra LifeSciences Holdings Corporation, MiMedx Group Inc., MISONIX Inc., Organogenesis Holdings Inc., SANUWAVE Inc., Smith & Nephew plc, Vericel Corporation, Wright Medical Group N.V. (Stryker Corporation).

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the wound biologics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: skin substitutes (CTPs), and others
Wound type: acute wounds, and chronic wounds
End user: hospitals, and clinics
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the global wound biologics market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global wound biologics market looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Wound Biologics Market by Product
4.1 Skin Substitutes (Ctps)
4.2 Others
5. Wound Biologics Market by Wound Type
5.1 Acute Wounds
5.2 Chronic Wounds
6. Wound Biologics Market by End User
6.1 Hospitals
6.2 Clinics
7. Wound Biologics Market by Region
7.1 North America
7.2 Asia Pacific
7.3 Europe
7.4 Rest Of The World (Row)
8. Company Profiles
8.1 Allergan plc (AbbVie Inc.)
8.2 Amniox Medical, Inc.
8.3 Cook Biotech Inc.
8.4 Integra LifeSciences Holdings Corporation
8.5 MiMedx Group, Inc.
8.6 MISONIX, Inc.
8.7 Organogenesis Holdings Inc.
8.8 SANUWAVE, Inc.
8.9 Smith & Nephew plc
8.10 Vericel Corporation
8.11 Wright Medical Group N.V. (Stryker Corporation)
9. Appendix
9.1 About StrategyHelix
9.2 Disclaimer